Purple Biotech Ltd (TLV:PPBT)
Israel · Delayed Price · Currency is ILS · Price in ILA 1.000
0.00 (0.00%)
Jul 27, 2026, 5:24 PM IDT
Purple Biotech Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -26.02 | -26.39 | -7.24 | -19.88 | -21.67 | -18.38 |
Depreciation & Amortization | 0.22 | 0.2 | 0.19 | 0.2 | 0.2 | 0.23 |
Asset Writedown & Restructuring Costs | 20.48 | 20.48 | 0.2 | - | - | - |
Stock-Based Compensation | 0.31 | 0.31 | 0.58 | 1.88 | 2.41 | 2.08 |
Other Operating Activities | -2.28 | -1.07 | -3.77 | -2.39 | -0.94 | 0.45 |
Change in Accounts Payable | -0.2 | 0.45 | -2.08 | 1.33 | 0.8 | 0.4 |
Change in Other Net Operating Assets | 0.69 | 0.36 | -2.26 | -1.06 | 2.46 | 0.35 |
Operating Cash Flow | -6.8 | -5.66 | -14.37 | -19.93 | -16.74 | -15.25 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -0 | -0 | - | -0 | -0.03 | -0.12 |
Cash Acquisitions | - | - | - | -3.55 | - | - |
Sale (Purchase) of Intangibles | - | - | - | - | -0.2 | - |
Investment in Securities | 0.23 | 0.45 | 0.19 | 16.68 | 19.66 | 10.25 |
Other Investing Activities | 0.19 | 0.19 | 0.32 | 0.76 | 0.48 | 3.27 |
Investing Cash Flow | 0.42 | 0.63 | 0.51 | 13.88 | 19.91 | 13.41 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Repaid | - | -0.22 | -0.18 | -0.17 | -0.17 | -0.15 |
Total Debt Repaid | -0.22 | -0.22 | -0.18 | -0.17 | -0.17 | -0.15 |
Net Debt Issued (Repaid) | -0.22 | -0.22 | -0.18 | -0.17 | -0.17 | -0.15 |
Issuance of Common Stock | 2.93 | 3.15 | 7.84 | 1.56 | 1.5 | 1.76 |
Other Financing Activities | 3.46 | 3.4 | -0.88 | 4.05 | -0.22 | -0.1 |
Financing Cash Flow | 6.17 | 6.33 | 6.77 | 5.45 | 1.11 | 1.51 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | 0.01 | 0.01 | -0 | 0.05 | -0.15 | -0.02 |
Net Cash Flow | -0.21 | 1.32 | -7.09 | -0.54 | 4.14 | -0.36 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -6.8 | -5.66 | -14.37 | -19.93 | -16.76 | -15.37 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -0.01 | -0.01 | -0.04 | -0.09 | -0.09 | -0.09 |
Levered Free Cash Flow | -2.5 | -0.05 | -11.7 | -8.43 | -8.8 | -7.64 |
Unlevered Free Cash Flow | -2.5 | -0.05 | -11.7 | -8.43 | -8.8 | -7.64 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash Interest Paid | 0.02 | 0.02 | 0.04 | 0.06 | 0.07 | 0.08 |
Change in Working Capital | 0.49 | 0.81 | -4.33 | 0.27 | 3.26 | 0.74 |